Drugs and Devices

New combination drug treatment may successfully treat cystic fibrosis

A combination of the drugs Kalydeco (ivacaftor) and lumacaftor, which has not yet been approved by the Food and Drug Administration (FDA), can successfully treat the underlying cause of cystic fibrosis for patients age 12 and older with two copies of the F508del gene mutation (the most common form of the disease), according to two phase 3 clinical trials published in the New England Journal of Medicine. Read more.


Related Articles:

Leave a Reply

You have to agree to the comment policy.

 

Newsletter Subscribe

  • This field is for validation purposes and should be left unchanged.

Test Your Nursing Knowledge

Answer this interactive quiz to be entered to win a gift card.

  • This field is for validation purposes and should be left unchanged.

Insights Blog

Today’s News in Nursing

Shares